⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 5, 2025Science Immunology

Loss-of-function mutations ensure that response to immune checkpoint therapy is NOD2 be denied

Ana C. Anderson Manu Rangachari

View Full Paper

Ask AI

Bookmark

Share

Key Points

Loss-of-function mutations in NOD2 may enhance responsiveness to PD-1 blockade therapy in cancer.
Patients with NOD2 mutations showed a potentially positive response to monotherapy with PD-1 inhibitors.
The study focused on the relationship between NOD2 mutations and immune checkpoint therapy outcomes.
Finding correlations highlights the significance of genetic factors in tailoring immune checkpoint therapy.

Abstract

Loss-of-function mutations in NOD2 may predict positive response to PD-1 blockade monotherapy in cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anderson et al. (2025) studied this question.

synapsesocial.com/papers/68c193fb9b7b07f3a061859b https://doi.org/10.1126/sciimmunol.aeb8333

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Original Research · 2019 · 45 citations
2NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis2024
3NEDD8 loss causes cancer vulnerability to immune checkpoint blockade in triple-negative breast cancer2024 · 1 citations
4Differential signaling through the PD-1 receptor allows for a distinct inhibitory signature and unique signal dichotomy between PD-L1 and PD-L2 2261044Original Research · 2026
5Functional consequences of NOD2 (CARD15) mutationsOriginal Research · 2006 · 129 citations